Last reviewed · How we verify

Buprenorphine Buccal Film [Belbuca]

Carolinas Pain Institute · FDA-approved active Small molecule

Buprenorphine Buccal Film [Belbuca] is a Partial mu-opioid receptor agonist Small molecule drug developed by Carolinas Pain Institute. It is currently FDA-approved for Chronic pain in opioid-tolerant patients. Also known as: Belbuca.

Buprenorphine is a partial mu-opioid receptor agonist that binds with high affinity to opioid receptors in the central nervous system to provide analgesia and reduce pain perception.

Buprenorphine is a partial mu-opioid receptor agonist that binds with high affinity to opioid receptors in the central nervous system to provide analgesia and reduce pain perception. Used for Chronic pain in opioid-tolerant patients.

At a glance

Generic nameBuprenorphine Buccal Film [Belbuca]
Also known asBelbuca
SponsorCarolinas Pain Institute
Drug classPartial mu-opioid receptor agonist
TargetMu-opioid receptor (μ-OR)
ModalitySmall molecule
Therapeutic areaPain Management
PhaseFDA-approved

Mechanism of action

Buprenorphine acts as a partial agonist at the mu-opioid receptor, meaning it produces a submaximal response compared to full agonists while maintaining high receptor binding affinity. This partial agonist profile provides analgesic efficacy with a lower ceiling effect on respiratory depression compared to full opioid agonists. The buccal film formulation allows transmucosal absorption for rapid onset of pain relief in chronic pain management.

Approved indications

Common side effects

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Buprenorphine Buccal Film [Belbuca]

What is Buprenorphine Buccal Film [Belbuca]?

Buprenorphine Buccal Film [Belbuca] is a Partial mu-opioid receptor agonist drug developed by Carolinas Pain Institute, indicated for Chronic pain in opioid-tolerant patients.

How does Buprenorphine Buccal Film [Belbuca] work?

Buprenorphine is a partial mu-opioid receptor agonist that binds with high affinity to opioid receptors in the central nervous system to provide analgesia and reduce pain perception.

What is Buprenorphine Buccal Film [Belbuca] used for?

Buprenorphine Buccal Film [Belbuca] is indicated for Chronic pain in opioid-tolerant patients.

Who makes Buprenorphine Buccal Film [Belbuca]?

Buprenorphine Buccal Film [Belbuca] is developed and marketed by Carolinas Pain Institute (see full Carolinas Pain Institute pipeline at /company/carolinas-pain-institute).

Is Buprenorphine Buccal Film [Belbuca] also known as anything else?

Buprenorphine Buccal Film [Belbuca] is also known as Belbuca.

What drug class is Buprenorphine Buccal Film [Belbuca] in?

Buprenorphine Buccal Film [Belbuca] belongs to the Partial mu-opioid receptor agonist class. See all Partial mu-opioid receptor agonist drugs at /class/partial-mu-opioid-receptor-agonist.

What development phase is Buprenorphine Buccal Film [Belbuca] in?

Buprenorphine Buccal Film [Belbuca] is FDA-approved (marketed).

What are the side effects of Buprenorphine Buccal Film [Belbuca]?

Common side effects of Buprenorphine Buccal Film [Belbuca] include Dizziness, Headache, Nausea, Constipation, Somnolence, Application site irritation.

What does Buprenorphine Buccal Film [Belbuca] target?

Buprenorphine Buccal Film [Belbuca] targets Mu-opioid receptor (μ-OR) and is a Partial mu-opioid receptor agonist.

Related